17-58734181-A-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_058216.3(RAD51C):c.1090A>G(p.Ser364Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000233 in 1,461,212 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_058216.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD51C | NM_058216.3 | c.1090A>G | p.Ser364Gly | missense_variant | 9/9 | ENST00000337432.9 | NP_478123.1 | |
LOC105371843 | XR_007065866.1 | n.81-9756T>C | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51C | ENST00000337432.9 | c.1090A>G | p.Ser364Gly | missense_variant | 9/9 | 1 | NM_058216.3 | ENSP00000336701 | P2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000400 AC: 1AN: 250248Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135196
GnomAD4 exome AF: 0.0000233 AC: 34AN: 1461212Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 726816
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 16, 2023 | This missense variant replaces serine with glycine at codon 364 of the RAD51C protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in individuals affected with breast cancer (PMID: 22476429), but also in unaffected individuals (PMID 26261251; https://whi.color.com/variant/17-56811542-A-G.). This variant has been identified in 2/281650 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 14, 2022 | The p.S364G variant (also known as c.1090A>G), located in coding exon 9 of the RAD51C gene, results from an A to G substitution at nucleotide position 1090. The serine at codon 364 is replaced by glycine, an amino acid with similar properties. This alteration has been reported in a high-risk breast and/or ovarian cancer family (Lu W et al. Fam. Cancer, 2012 Sep;11:381-5). Another study detected this alteration in 0/3429 patients with invasive epithelial ovarian cancer and 1/2772 unaffected controls (Song H et al. J. Clin. Oncol., 2015 Sep;33:2901-7). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Premature ovarian failure Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | Medical Cytogenetics and Molecular Genetics Laboratory, IRCCS Istituto Auxologico Italiano | Mar 02, 2020 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 10, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Observed in an individual with a personal history of breast cancer and a family history of breast and/or ovarian cancer (PMID: 22476429); Published functional studies demonstrate normal in vitro homology-directed repair (HDR) activity (PMID: 37253112); This variant is associated with the following publications: (PMID: 34480478, 26261251, 25470109, 26406419, 23117857, 34923718, 14704354, 22476429, 37253112) - |
Fanconi anemia complementation group O Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 364 of the RAD51C protein (p.Ser364Gly). This variant is present in population databases (rs587782565, gnomAD 0.002%). This missense change has been observed in individual(s) with breast cancer (PMID: 22476429, 26261251). ClinVar contains an entry for this variant (Variation ID: 142585). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Aug 30, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at